Earnings Summary

Allogene Therapeutics, Inc.’s revenue fell -48.84% since last year same period to $0.04Mn in the Q2 2023. On a quarterly growth basis, Allogene Therapeutics, Inc. has generated -15.38% fall in its revenue since last 3-months.

Allogene Therapeutics, Inc.’s net profit fell -4.28% since last year same period to $-77.99Mn in the Q2 2023. On a quarterly growth basis, Allogene Therapeutics, Inc. has generated 20.69% jump in its net profits since last 3-months.

Allogene Therapeutics, Inc.’s net profit margin fell -103.82% since last year same period to -177247.73% in the Q2 2023. On a quarterly growth basis, Allogene Therapeutics, Inc. has generated 6.27% jump in its net profit margins since last 3-months.

Allogene Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.7 - a -9.37% fall from last quarter’s estimates.

Allogene Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.7.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Allogene Therapeutics, Inc.’s return on assets (ROA) stands at -0.26.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Allogene Therapeutics, Inc.’s return on equity (ROE) stands at -0.5.